How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals?

The prevalence of nonalcoholic fatty liver disease (NAFLD) has reached global epidemic proportions,1 paralleling that of the increasing trends in the prevalence of obesity and type 2 diabetes (T2D). In fact, obesity is one of the most frequently associated comorbidities of NAFLD,2 and, furthermore,...

Descripción completa

Detalles Bibliográficos
Autores: Sookoian, Silvia Cristina, Pirola, Carlos José
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/38760
Acceso en línea:http://hdl.handle.net/11336/38760
Access Level:acceso abierto
Palabra clave:Alcohol Consumption
Fibrosis
Mendelian Randomization
Nafld
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
Descripción
Sumario:The prevalence of nonalcoholic fatty liver disease (NAFLD) has reached global epidemic proportions,1 paralleling that of the increasing trends in the prevalence of obesity and type 2 diabetes (T2D). In fact, obesity is one of the most frequently associated comorbidities of NAFLD,2 and, furthermore, NAFLD and obesity integrate the myriad risk factors for cardiovascular disease (CVD) clustered in the metabolic syndrome (MetS). By definition, NAFLD is characterized by abnormal liver fat accumulation in the absence of significant alcohol consumption and other causes of secondary hepatic steatosis. Once diagnosed, the treatment of NAFLD is complex and often requires pharmacologic intervention to control associated risk factors and/or lifestyle modifications. Conflicting results on whether social or moderate alcohol consumption (MAC) is detrimental or beneficial leave physicians uncertain as to whether or not to apply tight restrictions or allow low levels of social alcohol use for potential health benefit.